BRAF and cancer: In cell-based assays, Pz-1 selectively inhibited, in the low nM range, proliferation of cancer cell lines only when positive for RET or TRK-derived oncogenes, with negligible effects in cells carrying different driver oncogenes (RAS, BRAF, EGFR).